Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Authors:
- Philippe E. SpiessPSPhilippe E. Spiess
- Neeraj AgarwalNANeeraj Agarwal
- Rick BangsRBRick Bangs
- Stephen A. BoorjianSBStephen A. Boorjian
- Mark K. BuyyounouskiMBMark K. Buyyounouski
- Peter E. ClarkPCPeter E. Clark
- Tracy M. DownsTDTracy M. Downs
- Jason A. EfstathiouJEJason A. Efstathiou
- Thomas W. FlaigTFThomas W. Flaig
- Terence FriedlanderTFTerence Friedlander
- Richard E. GreenbergRGRichard E. Greenberg
- Khurshid A. GuruKGKhurshid A. Guru
Top Cited Papers
- 5 October 2017
- journal article
- research article
- Published by Harborside Press, LLC in Journal of the National Comprehensive Cancer Network
- Vol. 15 (10) , 1240-1267
Abstract
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive urothelial bladder cancer, as substantial revisions were made in the 2017 updates, such as new recommendations for nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab. The complete version of the NCCN Guidelines for Bladder Cancer addresses additional aspects of the management of bladder cancer, including non–muscle-invasive urothelial bladder cancer and nonurothelial histologies, as well as staging, evaluation, and follow-up.Keywords
This publication has 68 references indexed in Scilit:
- Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladderWorld Journal of Urology, 2015
- Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710Cancer, 2014
- Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH ExperienceEuropean Urology, 2012
- A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladderCancer, 2008
- The association between extent of lymphadenectomy and survival among patients with lymph node metastases undergoing radical cystectomyCancer, 2008
- Discrepancy between Clinical and Pathologic Stage: Impact on Prognosis after Radical CystectomyEuropean Urology, 2007
- Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEuropean Journal of Cancer, 2006
- Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005
- Adjuvant Chemotherapy in Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient DataEuropean Urology, 2005
- Neoadjuvant Cisplatinum Based Combination Chemotherapy in Patients with Invasive Bladder Cancer: A Combined Analysis of Two Nordic StudiesEuropean Urology, 2004